Results

1–4 of 4 results for Macular telangiectasia type 2

Phase 3 Randomized Studies of Efficacy and Safety of Revakinagene Taroretcel Producing Ciliary Neurotrophic Factor (CNTF) in Macular Telangiectasia Type 2
Emily Y. Chew, MD
Annual Meeting Talks
2023
Pooled Clinical Trial Safety Data of Neurotrophic Factorâ€“Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
Paul S. Bernstein, MD, PhD
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor-Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Annual Meeting Talks
2024
Post Hoc Analyses of Responder Status in Phase 3 Studies of Ciliary Neurotrophic Factor–Producing Revakinagene Taroretcel in People With Macular Telangiectasia Type 2
John A. Wells, MD, FACS
Updates from the Field
2024